The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in June 2020 concern various types of devices, including total lumbar disc prostheses, arthroscopic meniscal repair system, vagus nerve stimulation system, and medical aids. A total of 10 decisions were made.

The Health Institute Carlos III (ISCIII) in Spain analyzed the effectiveness and safety of the endovenous ablation of varicose saphenous veins with cyanoacrylate closure system in patients with moderate to severe chronic venous insufficiency compared to surgical procedures, as of saphenous vein stripping, and other endovenous ablation techniques. In the report, published on the website in 2020, it was outlined that despite the limitations found in selected studies, intravenous sealing with cyanoacrylates seems to be a promising alternative to existing treatments, especially in terms of less use of anesthesia and compression bandage, as well as shorter recovery time.

In June 2020, two new apps entered the level 1 of the mHealthBelgium validation pyramid. Guardian Connect smartphone application is a component of the Guardian Connect Continuous Glucose Monitoring (CGM) system for diabetes management. The icompanion software is a decision-making tool that helps physicians to choose medication for patients with multiple sclerosis.

On 9 May 2020, the Reimbursement Commission made changes to the SUT regarding response to the COVID-19 pandemic and introduced codes for IVD tests for Covid-19 (SARS-CoV-2) reverse transcriptase PCR and detection of Covid-19 antigen, IgG, IgM.

In early June 2020, the Austrian Ministry of Health published recommendations for further actions in the establishment of systematic HTA in the Austrian healthcare system, which were developed by the Federal Target Steering Commission in April.

On June 23, 2020, the Swiss Federal Office of Public Health (FOPH) announced several changes in the coverage of benefits that will take place soon. They regard transcatheter aortic valve implantation (TAVI), adjustments in the List of Aids (EMAp/MiGeL) (including reimbursement for CPAP devices and mechanical ventilation at home, and adjustments in the List of Analyses (AL/EA).

The reimbursement for PCR tests for the detection of SARS-CoV-2 will be reduced from €59.00 to €39.40 per test starting from July 1, 2020, and the billing of the examination will be limited to five times in the case of treatment. This decision was made by the extended evaluation committee on June 10, 2020.

From June 2020, NHS England will provide patients with cystic fibrosis and those recovering from coronavirus with devices and apps so physicians can track their condition remotely as part of the NHS drive to deliver connected, assisted, personalized care to more individuals in their own homes.

The Swiss cantons are required to jointly draw up a plan for the provision of highly specialized medical treatments (MHS). Until September 2020, the Conference of Cantonal Health Directors is discussing whether complex gynecological tumors, pediatric oncology, bariatric surgery, highly specialized pediatric surgery, and other areas of care should enter the MHS.

In 2019, the Health Institute Carlos III (ISCIII) assessed the effectiveness of hyperbaric oxygen therapy (HBOT) in the treatment of fibromyalgia, peripheral vascular disease, neurological disease, and others. The report was published online in 2020. The previous assessment, performed in 2018, was related to the use of HBOT in patients with Complex Regional Pain Syndrome (CRPS).

In the middle of May 2020, Västra Götaland HTA-Centre published an HTA on magnetic resonance image-guided radiotherapy in patients with cancer aiming to assess whether the studied method improves treatment results compared to current methods. It was concluded that the new technique might be associated with a higher proportion of treatment sessions reaching target coverage goals and a lower number of treatment sessions with violations of organs at risk constraints. However, the extent of improvement varied substantially between studies, and the certainty of the evidence is low.